NCT04603300View on ClinicalTrials.gov

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 15, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Peanut Allergy
Interventions
DRUG

INT301

INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste

DRUG

Placebo

Fully functional toothpaste containing no immunotherapy agents

Trial Locations (2)

07109

Hudson-Essex Allergy, Belleville

07457

Weiss Medical, Riverdale

Sponsors
All Listed Sponsors
lead

Intrommune Therapeutics

INDUSTRY